XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Financial Assets and Liabilities - Additional Information (Detail)
€ / shares in Units, $ / shares in Units, € in Thousands
1 Months Ended 3 Months Ended
Mar. 29, 2022
EUR (€)
Mar. 29, 2022
USD ($)
Sep. 30, 2023
USD ($)
Multiple
XBB
Mar. 31, 2024
EUR (€)
Days
Agreement
€ / shares
Mar. 31, 2024
USD ($)
Days
Agreement
Mar. 31, 2024
USD ($)
$ / shares
Dec. 31, 2023
EUR (€)
€ / shares
Disclosure of detailed information about financial instruments [line items]              
Derivative liabilities       € 197,291     € 143,296
Convertible Senior Notes       425,000     € 407,100
Fair Value of Convertible Notes       € 387,300      
Share price | € / shares       € 50.2     € 50.47
Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount | XBB     1.925        
Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount | XBB     1.65        
Carrying amount of royalty funding liabilities       € 146,200      
Fair value of royalty funding liabilities       150,200      
Royalty Pharma [member]              
Disclosure of detailed information about financial instruments [line items]              
Funding received in exchange of royalty payments | $     $ 150,000,000        
Net proceeds after deduting offering expenses       € 136,300 $ 146,300,000    
Royalty payment ending period     Dec. 31, 2031        
Royalty Pharma [member] | Bottom of range [member]              
Disclosure of detailed information about financial instruments [line items]              
Multiple of the purchase price were royalty payment will cease | Multiple     1.65        
Royalty Pharma [member] | Top of range [member]              
Disclosure of detailed information about financial instruments [line items]              
Multiple of the purchase price were royalty payment will cease | Multiple     1.925        
U.S. SKYTROFA [member]              
Disclosure of detailed information about financial instruments [line items]              
Funding received in exchange | $     $ 150,000,000        
Revenue interest payment in percentage in exchange for funding     9.15%        
Royalty payment beginning period     Jan. 01, 2025        
Historical volatility for shares, measurement input [member] | Derivatives [member]              
Disclosure of detailed information about financial instruments [line items]              
Percentage of reasonably possible increase in unobservable input, liabilities       10.00%   10.00%  
Percentage of reasonably possible decrease in unobservable input, liabilities       10.00%   10.00%  
Share Price Measurement Input [Member] | Derivatives [member]              
Disclosure of detailed information about financial instruments [line items]              
Increase decrease in derivative financial liabilities fair value       € 35,500      
Percentage of reasonably possible increase in unobservable input, liabilities       10.00%   10.00%  
Percentage of reasonably possible decrease in unobservable input, liabilities       10.00%   10.00%  
Foreign Currency Conversion Option [Member]              
Disclosure of detailed information about financial instruments [line items]              
Increase decrease in derivative financial liabilities fair value       € 16,200      
American depository shares [member]              
Disclosure of detailed information about financial instruments [line items]              
Conversion price per share | $ / shares           $ 166.34  
Convertible Senior Notes [Member]              
Disclosure of detailed information about financial instruments [line items]              
Conversion rate per note | $ / shares           $ 6.0118  
Principal amount | $   $ 575,000,000          
Borrowings redemption period       April 7, 2025 April 7, 2025    
Borrowings condition for redemption       but only if the last reported sale price per ADS exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice. but only if the last reported sale price per ADS exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice.    
Borrowings threshold percentage of sale price per share for redemption       130.00% 130.00%    
Borrowings threshold trading days for redemption | Days       20 20    
Borrowings threshold consecutive trading days for redemption | Agreement       30 30    
Proceeds from issue of bonds, notes and debentures € 503,300 $ 557,900,000          
Borrowings, maturity April 1, 2028 April 1, 2028   April 1, 2028 April 1, 2028    
Convertible Senior Notes [Member] | American depository shares [member]              
Disclosure of detailed information about financial instruments [line items]              
Principal amount | $           $ 1,000  
Fixed interest rate [member] | Convertible Senior Notes [Member]              
Disclosure of detailed information about financial instruments [line items]              
Borrowings Interest Rate   2.25%   2.25%   2.25%